United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

The COVID-19 vaccine developed by Pfizer and BioNTech now has less stringent and extreme transportation requirements than it debuted with. Originally, the mRNA-based vaccine had to be maintained at ultra-low temperatures throughout the transportation chain in order to remain viable – between -76°F and -112°F.

Pfizer-BioNTech's COVID-19 vaccine just got a lot easier to transport and distribute

Pfizer is seeking permission from the FDA to store its vaccine for two weeks at temperatures commonly found in pharmaceutical freezers and refrigerators.

Pfizer asks FDA to approve storing Covid vaccine doses at higher temperatures

Shares of Pfizer Inc. gained 0.1% in premarket trading on Friday after the drugmaker said it is requesting a regulatory change to the storage requirements for the COVID-19 vaccine it developed with BioNTech SE . BioNTech's stock was down 0.8%.

BioNTech, Pfizer say their COVID-19 vaccine can be stored at higher temperatures than previously thought

The researchers said the findings support policies delaying the second shot in efforts to stretch supplies and speed up immunizations.

Single Shot Of Pfizer-BioNTech Covid-19 Vaccine Is 85% Effective, Study Finds

The first dose of Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) vaccine could be highly efficacious against COVID-19, a study has found — fueling debate over delaying the second dose to stretch supplies, Reuters reported Thursday. What Happened: The first dose of the Pfizer vaccine could be 85% effective, according to a study of healthcare workers at Israel's Sheba Medical Center, Reuters noted.

Delay Pfizer COVID-19 Vaccine's 2nd Inoculation To Boost Supply? Here's What Research Is Saying

The testing will also be extended to children.

Pfizer and BioNTech Launch Coronavirus Vaccine Study for Pregnant Women

Fitbit

Gildan Activewear

Merck

NetEase

Prem Watsa (Trades, Portfolio), the founder and chairman of Fairfax Financial Ltd. (TSX:FFH), disclosed this week that his insurance company's top five trades during the fourth quarter featured new positions in Pfizer Inc. (NYSE:PFE) and Merck & Co. (NYSE:MRK) and the closure of his holdings in Fitbit Inc. (NYSE:FIT), Gildan Activewear Inc. (NYSE:GIL) and NetEase Inc. (NASDAQ:NTES).

Prem Watsa's Top 5 Trades of the 4th Quarter

AstraZeneca

Johnson & Johnson

Novavax

As Covid-19 becomes endemic, rich governments will turn to Novavax to vaccinate people in developing economies. NVAX stock will benefit.

NVAX Stock Is the Most Undervalued Vaccine Maker for Endemic Covid-19

Pfizer Inc. and partner BioNTech SE said Thursday that they have commenced a clinical trial to evaluate their COVID-19 vaccine in pregnant women. The companies said the Phase 2/3 trial will enroll 4,000 health pregnant women in the U.S., Canada, Argentina, Brazil, Chile, Mozambique, South Africa, the United Kindom and Spain, with the first participants dosed in the U.S. "We are proud to start this study in pregnant women and continue to gather the evidence on safety and efficacy to potentially support the use of the vaccine by important subpopulations," said William Gruber, senior vice president of vaccine clinical research and development at Pfizer.

Pfizer, BioNTech have started trial to evaluate their COVID-19 vaccine in pregnant women

Pfizer (PFE)/BioNTech (BNTX) win a deal for 200 million more doses of its COVID-19 vaccine in Europe.

Pfizer/BioNTech to Sell More COVID-19 Vaccine Doses to EU

A laboratory study suggests that a COVID-19 mutant strain prevalent in South Africa may lower antibody protection from the Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) vaccine and it is not clear if the shot will be effective against the mutation, reports Reuters. Though the lab study found the vaccine was still able to neutralize the virus.

Pfizer Says South African Variant Could Significantly Reduce Vaccine Protection

Moderna

Insiders at Pfizer Inc. (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) and other COVID-19 vaccine makers collectively sold nearly half a billion dollars worth of their stock but one pro isn't alarmed by the trend, The Wall Street Journal reported. What are insider trades?

What to make of Pfizer, Moderna insiders dumping stock?

Pfizer Inc. and BioNTech SE said late Wednesday its COVID-19 vaccine provided protection against the South African variant of the novel coranovirus in a lab study. The study, conducted by Pfizer and the University of Texas Medical Branch and not done in humans, investigated the full set of South African variant spike mutations.

Pfizer, BioNTech COVID-19 vaccine likely to protect against South Africa strain

These two pharma giants' recent struggles in the stock market represent a buying opportunity.

2 Top Stocks to Buy for a Post-Pandemic World

Pfizer-BioNTech to supply 200 million additional COVID-19 vaccine doses to EU

Pfizer has not yet delivered to the European Union about 10 million COVID-19 vaccine doses that were due in December, EU officials said, leaving it about one-third short of the supplies it had expected by now from the U.S. company.

Exclusive: Pfizer's COVID-19 vaccine supply to the EU 30% below plans, sources say

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the first participant has been dosed in the registration-enabling Phase 2 MagnetisMM-3 study (NCT04649359) of elranatamab (PF-06863135), an investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody, in patients with relapsed/refractory multiple myeloma. The study evaluates the efficacy and safety of elranatamab, administered subcutaneously, in patients with disease that is refractory to at least one a

Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma

The European Commission has announced an agreement with Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) for 200 million more doses of its COVID-19 vaccine in addition to the 300 million doses committed to the EU through this year.  The EC has the option to request a supply of an additional 100 million doses.

Europe Calls On Pfizer/BioNtech For 200M More COVID-19 Vaccine Doses

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the European Commission (EC) to supply an additional 200 million doses of COMIRNATY®, the companies' COVID-19 Vaccine, to the 27 European Union (EU) member states. The EC has the option to request supply of an additional 100 million doses. This new agreement is in addition to the 300 million doses that have already been committed to the EU through 2021 under the f

Pfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of COMIRNATY®

Tensions between Taiwan and China have risen sharply during the Covid-19 pandemic as the island has accused the Chinese government of aggravating the pandemic.

Taiwan Says Deal To Buy 5 Million Pfizer-BioNTech Covid-19 Vaccines On Hold, Hints At Pressure From China

The FDA has approved Pfizer Inc's (NYSE: PFE) supplemental marketing application seeking approval for PANZYGA (immune globulin intravenous, human - ifas) for chronic inflammatory demyelinating polyneuropathy (CIDP), caused by damage to the covering of the nerves, called myelin, and is characterized by motor and sensory loss and weakness associated with loss of deep tendon reflexes. According to the company, PANZYGA is the only intravenous immunoglobulin (IVIg) with two FDA-approved maintenance dosing options for CIDP.

Pfizer's PANZYGA Wins FDA Approval For Rare Peripheral Nerves Disorder

The isolated country has previously been accused of targeting researchers and pharma companies for sensitive information on the pandemic.

Report: North Korean Hackers Tried To Steal Covid-19 Vaccine Tech From Pfizer

There's more good news for Pfizer's COVID-19 vaccine.

Pfizer Could Be an Even Bigger Winner After These 2 Fantastic Findings

Pfizer's (PFE) Panzyga gets FDA approval to treat chronic inflammatory demyelinating polyneuropathy (CIDP), a rare neurological disease.

Pfizer (PFE) Gets FDA Nod for New Indication of Immunoglobulin

AbbVie

Aflac

CNA Financial

Fidelity National Financial

Prudential Financial

When we find cash flow machines like the eight dividend payers we're about to discuss, we're talking about decades of payments.

News for Pfizer Stock (PFE)